Calendar
56th ASH Annual Meeting and Exposition
December 6 – 9, 2014
Moscone Center, San Francisco, CA
The American Society of Hematology (ASH) invites you
to attend the 56th ASH Annual Meeting in San Francisco,
California. As the premier hematology event, this meeting will provide attendees with an invaluable educational
experience. For a preview of the “Special Symposium on
Quality” turn to page 55.
Marqibo® (vinCRIStine sulfate LIPOSOME injection) BRIEF SUMMARY
Please see the Marqibo package insert for full Prescribing Information.
WARNING
• For Intravenous Use Only—Fatal if Given by Other Routes.
• Death has occurred with intrathecal administration.
• Marqibo (vinCRIStine sulfate LIPOSOME injection) has different dosage
recommendations than vinCRIStine sulfate injection. Verify drug name and
dose prior to preparation and administration to avoid overdosage.
INDICATIONS AND USAGE
Adult ALL in Second or Greater Relapse
Marqibo® is indicated for the treatment of adult patients with Philadelphia chromosomenegative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose
disease has progressed following two or more anti-leukemia therapies. This indication is
based on overall response rate. Clinical benefit such as improvement in overall survival has
not been verified.
DOSAGE AND ADMINISTRATION
For Intravenous Use Only—Fatal if Given by Other Routes.
Marqibo (vinCRIStine sulfate LIPOSOME injection) has different dosage recommendations
than vincristine sulfate injection. Verify drug name and dose prior to preparation and
administration to avoid overdosage.
Recommended Dosage
The recommended dose of Marqibo is 2.25 mg/m2 intravenously over 1 hour once every
7 days. Marqibo is liposome-encapsulated vincristine.
Dose Modifications: Peripheral Neuropathy
Marqibo is contraindicated in patients with demyelinating conditions including CharcotMarie-Tooth syndrome [see Contraindications]. Patients with preexisting severe neuropathy
should be treated with Marqibo only after careful risk-benefit assessment [see Warnings
and Precautions]. For dose or schedule modifications guideli